Cargando…
Exploratory Phase II Multicenter, Open-Label, Clinical Trial of ST266, a Novel Secretome for Treatment of Persistent Corneal Epithelial Defects
OBJECTIVE: An exploratory phase II, multicenter, open-label, clinical trial (NCT03687632) was conducted to evaluate the safety and effectiveness in treating persistent corneal epithelial defects (PEDs) with ST266, a proprietary novel multi-cytokine platform biologic solution secreted by cultured Amn...
Autores principales: | Jeng, Bennie H., Hamrah, Pedram, Kirshner, Ziv Z., Mendez, Benjamin C., Wessel, Howard C., Brown, Larry R., Steed, David L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Association for Research in Vision and Ophthalmology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742509/ https://www.ncbi.nlm.nih.gov/pubmed/34994777 http://dx.doi.org/10.1167/tvst.11.1.8 |
Ejemplares similares
-
Neuroprotection mediated by ST266 requires full complement of proteins secreted by amnion-derived multipotent progenitor cells
por: Willett, Keirnan, et al.
Publicado: (2021) -
Topical application of ST266 reduces UV-induced skin damage
por: Guan, Linna, et al.
Publicado: (2017) -
Corneal Allograft Rejection: Immunopathogenesis to Therapeutics
por: Qazi, Yureeda, et al.
Publicado: (2013) -
Characteristics of Toxic Keratopathy, an In Vivo Confocal Microscopy Study
por: Wang, Leying, et al.
Publicado: (2021) -
Corneal Subbasal Nerve Recovery in an Acute Case of Ultraviolet Keratitis Treated with Autologous Serum Eye Drops
por: Abedi, Farshad, et al.
Publicado: (2018)